Table 4.
Comparison of response rates for platinum- and bevacizumab-containing Phase II regimens for recurrent ovarian cancer.
| Authors | Agents | n | %PS | %PR | OR | 6-month PFS | Platinum- Sensitive | Platinum- Resistant | Combined Population | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| PFS | OS | PFS | OS | PFS | OS | |||||||
| Matulonis 2008 | Carbo + bev | 44 | 100 | - | 51 | NR | 7.6 | 20.3 | - | - | - | - |
| Sehouli 2011 | Carbo + pem | 61 | 100 | - | 33 | NR | 9.4 | NR | - | - | - | - |
| Burger 2007 | Bev | 62 | 58 | 42 | 21 | NR | - | - | - | - | 4.7 | 17 |
| Cannistra 2007 | Bev | 44 | - | 84 | 16 | NR | - | - | 4.4 | 10.7 | - | - |
| Garcia 2008 | Bev + oral cyclophos | 70 | 60 | 40 | 33 | 56 | 10 | 20 | 5 | 12 | 7.2 | 16.9 |
| McGonigle 2011 | Bev + topotecan | 40 | - | 100 | 25 | 55 | - | - | 7.8 | 16.6 | - | - |
| Kudoh 2011 | Bev + PLD | 30 | 4 | 96 | 33 | 47 | - | - | 6 | NR | - | - |
| del Carmen 2012 | Bev + PLD | 54 | 100 | - | 72 | NR | 14 | NR | - | - | - | - |
| Current Study | Bev + pem | 34 | 65 | 35 | 41 | 56 | 8.4 | 26.5 | 5.6 | 16.7 | 7.9 | 25.7 |
PS = platinum-sensitive; PR = platinum-resistant; OR = overall response; 6-month PFS = progression-free survival; PFS = median progression-free survival in months; OS = median overall survival in months; Bev = bevacizumab; pem = pemetrexed; cyclophos = cyclophosphamide; NR= not reported.